![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Direxion Daily Financial Bull 3X Shares ETF
FAS
Spdr S&P Bank Etf
KBE
Ultra Financials Proshares
UYG
4
SPDR S&P Metals & Mining ETF
XME
5
SPDR S&P Retail ETF
XRT
US Stock MarketDetailed Quotes
Kairos Pharma (KAPA)
- 0.7390
- +0.0017+0.23%
Close Dec 16 15:59 ET
- 0.7345
- -0.0045-0.61%
Post 20:01 ET
15.39MMarket Cap-3.04P/E (TTM)
0.7540High0.7101Low126.07KVolume0.7500Open0.7373Prev Close92.23KTurnover1.07%Turnover RatioLossP/E (Static)20.82MShares3.250052wk High2.01P/B8.73MFloat Cap0.400052wk Low--Dividend TTM11.81MShs Float4.0000Historical High--Div Yield TTM5.95%Range %0.4000Historical Low0.7310Avg Price1Lot Size
KAPA Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
KAPA Orderflow
Unit: --
KAPA Orderflow Trend
IntradayDayWeekMonth
No Data
Kairos Pharma (KAPA) News
Kairos Pharma's Promising Clinical Developments and Strategic Focus Drive Buy Rating
Kairos Pharma | 10-Q: Q3 2025 Earnings Report
12 Health Care Stocks Moving In Tuesday's After-Market Session
Kairos Pharma Price Target Maintained With a $9.00/Share by D. Boral Capital
Express News | Kairos Pharma Provides Shareholder Update
Promising Developments in Kairos Pharma's Lead Candidate ENV-105 Drive Buy Rating
Kairos Pharma (KAPA) Stock Forum
$Kairos Pharma (KAPA.US)$ watch list today
$Kairos Pharma (KAPA.US)$ can we see rebound tonight ?
1
$Kairos Pharma (KAPA.US)$
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
09/18/2025 - 05:00 AM
Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety data
Company to host virtual KOL discussion today to provide additional perspective on data and the Company’s lead program
LOS ANGELES--(BUSINESS W...
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
09/18/2025 - 05:00 AM
Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety data
Company to host virtual KOL discussion today to provide additional perspective on data and the Company’s lead program
LOS ANGELES--(BUSINESS W...
2
2
1
$Kairos Pharma (KAPA.US)$ why drop so much
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)
STACK BANDS SAVAGE : Watch list today!!